CD274 and non-small cell lung carcinoma: The use of different antibodies for PD-L1 and different immunohistochemistry procedures in assessing PD-L1 expression may lead to discrepancies in results; a study testing 3 different antibodies on NSCLC samples found that the antibodies were only moderately concordant in their positive rates [19].